Neoadjuvant Immune Checkpoint Inhibitors for Hepatocellular Carcinoma

Authors

• Vinita Akula
• Lily Chen
• Yusuf Acikgoz
• Katherine Klein
• Betul Gok Yavuz
• Lokman Cevik
• Tarik Demir
• Ashish Manne
• Ilyas Sahin
• Ahmed Kaseb
• Elshad Hasanov

Publication Date

3-6-2025

Journal

npj Precision Oncology

DOI

10.1038/s41698-025-00846-4

PMID

40050446

PMCID

PMC11885445

PubMedCentral® Posted Date

3-6-2025

PubMedCentral® Full Text Version

Post-print

Abstract

Hepatocellular carcinoma (HCC) is the most common type of liver cancer. HCC treatment is challenging; surgical resection is the primary curative treatment for early-stage disease, but recurrence rates are high. Immune checkpoint inhibitors (ICIs) are a promising neoadjuvant treatment that can reduce recurrence rates and mortality after surgery and achieve complete/partial responses. Clinical trials provide strong evidence for the efficacy and safety of ICI monotherapy for neoadjuvant HCC treatment.

Keywords

Cancer, Cancer immunotherapy

Published Open-Access

yes

Recommended Citation

Akula, Vinita; Chen, Lily; Acikgoz, Yusuf; et al., "Neoadjuvant Immune Checkpoint Inhibitors for Hepatocellular Carcinoma" (2025). Faculty, Staff and Student Publications. 3516.
https://digitalcommons.library.tmc.edu/uthmed_docs/3516